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Abstract 
We present the case of a 3%year-old woman with a severe ovarian hyperstimulation syndrome (OHSS) as a complication 
of ovulation induction for primary infertility. The clinical picture showed massively enlarged ovaries, pleural effusion and 
haemoconcentration. She needed a thoracentesis for evacuation of the large pleural effusion. High levels of renin and 
prorenin were observed in plasma and pleural exudate. 0 1997 Elsevier Science B.V. 
Keywords: Ovarian hyperstimulation syndrome; Renin-angiotensin system; Pleural effusion; Thoracentesis 
1. Introduction 
The ovarian hyperstimulation syndrome (OHSS) 
is an iatrogenic complication of both ovulation in- 
duction and ovarian hyperstimulation affecting other- 
wise healthy young women. In its most pronounced 
form, the clinical picture of OHSS is dominated by 
massive enlargement of the ovaries, ascites, pleural 
effusion, oliguria, serum electrolyte disturbances and 
hypercoagulability. The pathophysiological mecha- 
nisms underlying this syndrome are not fully known 
and no specific treatment is available [l-3]. We 
present here a patient with a severe form of OHSS 
and discuss the clinical picture, pathophysiology and 
treatment. 
2. Case report 
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Veldhoven, the Netherlands (poster presentation). Published as 
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Ouwendijk, RJTh. High renin and aldosterone but normal prosta- 
glandins in a patient with the ovarian hyperstimulation syndrome. 
Neth J Med 48:1996;A78, abstract 77. 
A 35-year-old woman who had a duodenal ulcer 
and sarcoidosis in her medical history, was being 
treated by the gynaecologist for primary infertility 
based on polycystic ovarian disease. She had not 
reacted to courses of clomiphene citrate. One month 
before admission she had started her first course of 
ovulation induction with human menopausal go- 
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nadotropin (hMG) and human chorionic go- 
nadotropin (hCG). She was treated with a step-up 
regime hMG (Pergonal, Serono, The Hague, The 
Netherlands) and needed a maximal dose of 150 IU 
hMG a day for response. After 20 days, very large 
ovaries were seen by transvaginal ultrasound, with in 
both ovaries one follicle cyst of 19 X 17 mm and 
many smaller follicular cysts. The possibility of the 
development of OHSS was discussed with the pa- 
tient, after which it was decided to continue with 
ovulation induction. A single dose of 10000 IU hCG 
(Pregnyl, Grganon, Oss, the Netherlands) was given 
intramuscularly. Frequent out-patient visits were ar- 
ranged, and bed rest at home was advised. After 5 
days, she started to suffer from abdominal pain, 
which increased during the following days. Ten days 
after the hCGl administration she was admitted to the 
hospital because of severe dyspnoea. 
She complained of shortness of breath on minimal 
exercise and while lying horizontally, abdominal 
pain, and thirst. On physical examination she was 
tachypnoeic (frequency 40/min). Her blood pressure 
was 110/65 mmHg, with a pulse rate of 88/n-&. 
Examination Iof the heart was normal. Lung ausculta- 
tion revealed diffusely spread rales and diminished 
breath sounds over the lower right hemithorax. Her 
abdomen was distended and tender on palpation. 
There were no clear signs of ascites, or of peripheral 
oedema. The haemoglobin level had increased over 
10 days from 8.3 to 9.5 mmol/l; the haematocrit had 
risen from 0.4,0 to 0.46%; platelet count from 3 13 000 
to 424000 per mm3. The pregnancy test was positive 
and an ultrasonic examination later revealed a twin 
pregnancy. Various specific laboratory values were 
determined which are summarized in Table 1. Of 
note are a highly activated renin-angiotensin-al- 
dosterone system, a normal angiotensin-converting 
enzyme (ACE) value, moderately elevated degrada- 
tion products of prostaglandins and atria1 natriuretic 
protein (ANP), and normal values for tumour necro- 
sis factor-o (TNF-o), the soluble TNF receptors, and 
arginine vasopressin (AVP). Chest X-ray showed a 
large pleural effusion in the right hemithorax and 
moderate pleural effusion in the left. There were no 
abnormalities indicating active sarcoidosis. Ultra- 
sound of the abdomen showed a small quantity of 
peritoneal fluid around greatly enlarged ovaries (over 
10 cm) with multiple follicular cysts. 
Table 1 
Laboratory values of the patient with OHSS 
Compounds a Body fluid Patient values Normal values 
Progesterone plasma 980 nmol/l 64-95 nmol/l b 
pleural exudate 651 nmol/l - 
Renin (total) plasma 4447 pU/ml 126-458 @J/ml 
pleural exudate 5738 @/ml - 
Prorenin plasma 3915 @/ml 112-407 $J/ml 
pleural exudate 5103 $J/ml - 
Renin (active) plasma 514 pJJ/ml 14-51 yU/ml 
pleural exudate 635 pJ/ml - 
Aldosterone plasma 1231 pg/ml < 300 pg/ml 
ACE plasma 8.6 mu/ml 8-22 mu/ml 
AVP plasma 0.6 w/d < 10 pg/ml 
ANP plasma 76 m-/ml 20-50 pg/ml 
TXB, urine 37 &ml < 22 pg/ml 
PGE, urine 50 pg/ml < 22 pg/ml 
PGF, a urine 19 pg/ml < 17 pg/ml 
Bio-TNF-oc plasma < 6 &ml <6pg/dc 
STNFR, plasma 1.33 rig/ml 1.08-2.03 ng/mI 
s-I-N% plasma 5.78 rig/ml 2.33-6.13 mg/ml 
a ACE, angiotensin-converting enzyme; AVP, argiuine vaso- 
pressin; ANP, atrial natriuretic protein; TXB,, degradation prod- 
uct of trombexan (TXA,); PGE,, degradation product of prosta- 
glandin; PGF,, , degradation product of prostacyclin (PGI,); bio- 
TNF-a, bioactive tumour necrosis factor-o; sTNFR,, soluble 
TNF receptor- 1; sTNFR, , soluble TNF receptor-2. 
b Reference values in first trimester of pregnancy. 
’ Detection level. 
The patient was treated in the intensive care unit 
by a right-sided thoracentesis and 1.5 1 exudative 
fluid was evacuated. For intravascular volume deple- 
tion, she received intravenous saline fluid and diure- 
sis could be maintained above a level of 30 ml/h. 
To prevent thromboembolic complications, low-dose 
heparin was given intravenously. The remaining 
pleural effusion resolved spontaneously and no com- 
plications occurred. After 11 days, she was dis- 
missed in clinically good health. The pregnancy did 
not last, however, and ended in a missed abortion. 
3. Discussion 
OHSS is a severe complication of ovulation in- 
duction. Its clinical spectrum varies from mild to 
life-threatening. Several deaths have been reported 
[ll. In mild forms, the ovaries are greatly enlarged 
causing abdominal distension and discomfort (grade 
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I), that may be accompanied by nausea, vomiting 
and/or diarrhoea (grade 2). Moderate (grade 3) 
OHSS has the features of mild OHSS plus ultrasonic 
evidence of ascites. In severe OHSS (grade 4), there 
is also clinical evidence of ascites and/or hydrotho- 
rax or breathing difficulties. Grade 5 severe OHSS 
has all the described features plus changes in blood 
volume, increased blood viscosity due to haemocon- 
centration, coagulation abnormalities, and dimin- 
ished renal perfusion and function [l]. In the most 
severe form, life-threatening complications are 
thromboembolic phenomena, renal failure, elec- 
trolyte disturbances, tense ascites and/or hydrotho- 
rax, and the adult respiratory distress syndrome [ 1,2]. 
The incidence of moderate and severe OHSS varies 
from 2 to 14%; the incidence of severe OHSS is 
below 2% in most series [1,3-51. Risk factors for 
developing severe OHSS are polycystic ovarian dis- 
ease, conceptual cycles, possibly multiple gestation, 
and luteal phase supplementation with hCG. Ovula- 
tion induction with gonadotropin-releasing hormone 
agonists (GnRHa) and hMG confers a higher risk 
compared to stimulation with clomiphene citrate or 
hMG (without GnRHa). Women developing severe 
OHSS have higher serum levels of oestradiol and 
multiple immature and intermediate ovarian follicles 
[2-61. Our patient had experienced no problems 
while using clomiphene citrate, but developed a se- 
vere (grade 5) OHSS after ovulation induction with 
hMG and hCG. She had multiple risk factors: poly- 
cystic ovarian disease; multiple small ovarian cysts 
after hMG administration; and a twin pregnancy. We 
realize that the decision to continue the treatment in 
our patient can be debated, taking into account all 
the many risk factors she had. For a woman who 
wants to become pregnant, it is difficult to decide on 
this matter as she may not oversee all possible 
consequences and risks of artificial ovarian stimula- 
tion. The development of OHSS can be prevented by 
discontinuation of the stimulation and withholding 
hCG administration. Ovulation will not then take 
place. Other measures have been proposed as well. It 
is advised to stop ovarian stimulation when serum 
oestradiol levels are high and many small follicles 
are seen by ultrasound [l-3,5,7]. Unfortunately, the 
oestradiol levels had not been measured in our pa- 
tient. 
The pathogenesis of OHSS is not clear. The tradi- 
tional hypothesis suggests an increase in vascular 
permeability, leading to leaking of intravascular fluid 
into third spaces and acute reduction of intravascular 
volume [ l,S]. The distribution of extravascular fluid 
in OHSS suggests leakage from mesothelial mem- 
branes, which may be most susceptible to mediators 
of OHSS. Possible mediatory factors causing in- 
creased capillary permeability are prostaglandins, ac- 
tivated factors of the renin-angiotensin system, cy- 
tokines and various vasoactive factors [8- 181. 
It has been shown that an ovarian renin-angio- 
tensin system is activated by gonadotrophins, result- 
ing in high prorenin levels in preovulatory follicles 
[8]. Ovarian angiotensin II has an important role in 
oocyte maturation and ovulation [ 191. In OHSS pa- 
tients, extremely high levels of renin, prorenin, and 
immunoreactivity for angiotensin II have been found 
in plasma and ascites [9- 131. A direct correlation 
between plasma renin activity and severity of OHSS 
has been shown [9]. We show here that in the pleural 
effusion in a patient with OHSS, similar high levels 
of renin and prorenin are present. The elevated com- 
ponents of the renin-angiotensin system are most 
likely of ovarian origin [lo,1 1.131. Why prorenin, 
renin and angiotensin II are more elevated in ascites 
and pleural fluid than in plasma is not known. Direct 
ovarian-peritoneal transfer of luteal fluid might oc- 
cur. Alternatively, changes in vascular or peritoneal 
permeability might change the influx-efflux equilib- 
rium at the level of the mesothelium, leading to a 
rise in concentration of these components in the 
peritoneal and pleural cavity [ 11,131. Angiotensin II 
might be the component that causes the increase in 
vascular permeability [8]. It is not known whether 
angiotensin II is activated by ACE, or whether an 
alternative pathway within the ovary could directly 
transform angiotensinogen into angiotensin II. The 
level of ACE in our patient was not elevated. An 
alternative pathway that activates angiotensin II 
would indicate that ACE inhibitors are not useful in 
the treatment of OHSS, but angiotensin II receptor 
blockers might prove beneficial in this syndrome 
[ill. 
Other possible mediators in OHSS are various 
components of the immune system that are known 
for their strong effects on vascular permeability. 
Cytokines, such as interleukin-2 (IL-2), IL-6, IL-8 
and TNF, have been found elevated in OHSS [ 14- 
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161. In some studies, however, II-2 and TNF levels 
were normal [l&16]. We also observed normal val- 
ues for TNF-or and soluble TNF receptors in our 
patient. Recently, vascular endotbelial growth factor 
(VEGF) has been proposed as a mediator in OHSS. 
VEGF was elevated in OHSS and blocking of the 
activity of VEGF by antiserum decreased capillary 
permeability in an animal model [ 17,181. 
An alternative hypothesis for the pathogenesis of 
OHSS has been proposed by Balasch et al., who 
showed that an early event in OHSS is intense 
peripheral arteriolar vasodilation [20,21]. The simul- 
taneous occurrence of vascular underfilling by capil- 
lary leakage and the arteriolar vasodilation leads to a 
hyperdynamic circulation failure with compensatory 
activation of sympathetic nervous systems and the 
renin-angiotensin system to maintain blood pres- 
sure. Prostaglandins might be activated to antagonize 
the renal vasoconstrictor effects of the renin-angio- 
tensin system. In our patient, we measured a slightly 
elevated urinary excretion of TXB,, PGE,, and 
PGF,,. Recently, endothelin, a potent naturally oc- 
curring vasoconstrictor compound, was found to be 
elevated in OHSS and the authors hypothesized a 
central role for this substance in the neurohormonal 
compensation for haemodynamic stress associated 
with OHSS [22]. 
Treatment of OHSS is based largely on empirical 
data. Mild OHSS requires no therapy apart from 
maintenance of oral hydration. Patients with moder- 
ate OHSS require close observation, preferably by 
hospitalisation, as rapid deterioration may occur, 
while severe OHSS urges immediate hospitalisation, 
eventually in an intensive care unit [2,3,7]. Haemat- 
ocrit concentration should be followed as this corre- 
lates best with severity of OHSS [21,23]. Other 
parameters to be monitored are electrolyte status, 
liver and kidlney function, and coagulation. Ultra- 
sonography to assess ovarian size and intraperitoneal 
fluid volume should be done on admittance and 
during follow-up, when necessary [2,3,7]. Hypo- 
volaemia is best treated by crystalloids (NaCl) and 
human albumin [2,3,7]. The use of diuretics is highly 
controversial, but they may be used when haemodilu- 
tion exists [;!,3,7,21]. Ascites is best treated with 
paracentesis under ultrasonic guidance to prevent 
eventual puncture of an ovarian follicle [23,24]. 
Pleural effusion may diminish following abdominal 
paracentesis, but in the case of pleural effusion 
without ascites, thoracentesis immediately improves 
the dyspnoea and may reverse the clinical course 
[25,26], as was also seen in our patient. Thromboem- 
bolic complications may be prevented by prophylac- 
tic use of heparin. In the most severe form, OHSS is 
complicated by multiple organ failure, which re- 
quires specific treatment in the intensive care unit 
[2,3]. There is no place for treatment with non- 
steroidal anti-inflammatory drugs or angiotensin- 
converting enzyme inhibitors, because, as described 
above, they have no proven effect in studies and they 
may block beneficial counteracting mechanisms in 
OHSS [1,2,21]. 
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